A novel molecular disease classifier for psoriasis and eczema
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Novel specific therapies for psoriasis and eczema have been developed, and they mark a new era in the treatment of these complex inflammatory skin diseases. However, within their broad clinical spectrum, psoriasis and eczema phenotypes overlap making an accurate diagnosis impossible in special cases, not to speak about predicting the clinical outcome of an individual patient. Here, we present a novel robust molecular classifier ( MC ) consisting of NOS 2 and CCL 27 gene that diagnosed psoriasis and eczema with a sensitivity and specificity of >95% in a cohort of 129 patients suffering from (i) classical forms; (ii) subtypes; and (iii) clinically and histologically indistinct variants of psoriasis and eczema. NOS 2 and CCL 27 correlated with clinical and histological hallmarks of psoriasis and eczema in a mutually antagonistic way, thus highlighting their biological relevance. In line with this, the MC could be transferred to the level of immunofluorescence stainings for iNOS and CCL 27 protein on paraffin‐embedded sections, where patients were diagnosed with sensitivity and specificity >88%. Our MC proved superiority over current gold standard methods to distinguish psoriasis and eczema and may therefore build the basis for molecular diagnosis of chronic inflammatory skin diseases required to establish personalized medicine in the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
Collaborative Association Study of Psoriasis (CASP), Tsoi, L. C., Genetic Analysis of Psoriasis Consortium, Psoriasis Association Genetics Extension, Wellcome Trust Case Control Consortium 2, Spain, S. L., Knight, J., Ellinghaus, E., Stuart, P. E., Capon, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2467 · Cited by 1,024
Self-citationBroad defects in epidermal cornification in atopic dermatitis identified through genomic analysis
Guttman-Yassky, E., Suárez-Fariñas, M., Chiricozzi, A., Nograles, K. E., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Lin, P., Bergman, R., Bowcock, A. M., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.031 · Cited by 268
Cited by
Tsoi, L. C., Rodriguez, E., Degenhardt, F., Baurecht, H., Wehkamp, U., Volks, N., Szymczak, S., Swindell, W. R., Sarkar, M. K., Raja, K., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.12.018 · Cited by 469
Self-citationBiomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-Yassky, E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.013 · Cited by 350
“Some biomarkers seem to reliably distinguish between AD and psoriasis (namely NOS2 and chemokine C-C motif ligand [CCL] 27/cutaneous T-cell–attracting chemokine [CTACK]), 8– 10 thus potentially improving the diagnosis and management of patients with psoriasiform dermatitis (Table II).”
BackgroundTape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis
He, H., Bissonnette, R., Wu, J., Diaz, A., Saint-Cyr Proulx, E., Maari, C., Jack, C., Louis, M., Estrada, Y., Krueger, J. G., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.048 · Cited by 229
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Seremet, T., Di Domizio, J., Girardin, A., Yatim, A., Jenelten, R., Messina, F., Saidoune, F., Schlapbach, C., Bogiatzi, S., Minisini, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54559-6 · Cited by 57
“Other studies using bulk transcriptomics 35,43 , single-cell RNA sequencing 44 , or spatial transcriptomics 45 have identi fi ed distinct gene signatures capable of categorizing only psoriasis and atopic dermatitis, but not other diseases.”
Self-citationEczematized psoriasis – a frequent but often neglected variant of plaque psoriasis
Lauffer, F., & Eyerich, K. (2023) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14991 · Cited by 24
Self-citationScheurer, J., Sauer, B., Focken, J., Giampetraglia, M., Jäger, A., Schürch, C. M., Weigelin, B., & Schittek, B. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050541 · Cited by 21
Meinel, M., Langreder, N., Schmitt, A., Technau-Hafsi, K., Hillig, C., Roenneberg, S., Bernklauová, A., Říčař, J., Kacerovská, D., Wobser, M., et al. (2025) · doi:10.1101/2025.10.18.25338021 · Cited by 2
Self-citation
Metadata
- Authors
- Garzorz‐Stark, N., Krause, L., Lauffer, F., Atenhan, A., Thomas, J., Stark, S. P., Franz, R., Weidinger, S., Balato, A., Mueller, N. S., Theis, F. J., Ring, J., Schmidt‐Weber, C. B., Biedermann, T., Eyerich, S., & Eyerich, K.
- Venue
- Experimental Dermatology
- Publisher
- Wiley
- Published
- 2016-09-29
- Volume
- 25
- Issue
- 10
- Pages
- 767-774
- ISSN
- 0906-6705 (ISSN-L)
- 1600-0625
- OpenAlex
- W2404269503
- Cited by
- 79
- References
- 4
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.